Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

11 Nov 2021

946.50

-1.42%

Alembic Pharmaceutical - Bottom of earnings + Reasonable Valuations - Company Update

Buy: Alembic Pharmaceuticals Ltd.

Target

Monarch Networth Capital Limited

Alembic Pharmaceuticals Ltd (ALPM') reported in-line numbers for Q2FY22 on the back of strong momentum in domestic business and better gross margins (~74% vs ~71% in Q1FY22). US business continued to remain under pressure on the back of pricing pressure in the base business and full impact of Theophylline competition in Q2FY22. Domestic business (ex Azithromycin) grew >30% YoY as per the management which was led both by margins and price hikes. On Rhizen, TG Therapeutics have guided USD 50mn sales for Ukoniq over next year which would entail higher royalty revenues. While the management has withdrawn its FY22 EPS guidance, higher launch rate, faster remediation of Injectable unit and approval for CLL indication remains key positive triggers for the medium term.We maintain BUY on the stock, with a March-23 TP of Rs1,200, thus an upside of 51% over the CMP. ALPM is currently trading ~18x / ~13x PE for FY22E / FY23E. Delay in Remediation of F3 (New Injectable Facility), USFDA action in Panelav F1 and domestic...

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

11 Nov 2021

946.50

-1.42%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products The company has invested ~ | 1800 crore in recent years in facilities geared mainly towards US formulations. As of Q2FY22, it has filed 214 ANDA and has 150 approvals with 98 launches in the US...

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

11 Nov 2021

946.50

-1.42%

Weakness in US outweighs strong performance in DF

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered in-line 2QFY22 earnings. Subdued performance in US/API was offset by a better-than-expected show in the Domestic Formulation (DF) segment. The YoY declining trend in the US business has reached a trough with the limited impact of price erosion and an increased pace of launches going forward. We lower our FY22E/FY23E EPS estimate by 7.5%/5.8%, factoring in a) a delay in successful compliance at injectables sites, b) gradual revival in US sales, and c) higher RM/logistics costs. We value ALPM at 18x 12M forward...

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

27 Jul 2021

946.50

-1.42%

Alembic Pharma (HOLD): US disappoints; acute-led recovery in domestic business

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

BOB Capital Markets Ltd.

ALPM reported a 42% YoY decline in Q1 EBITDA due to weak US sales led by increased competition in key molecules and launch delays

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

27 Jul 2021

946.50

-1.42%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Consequent PAT was at | 164.5 crore (down 45.4% YoY) What should investors do? Alembic's share price has grown by ~1.7x over the past five years (from ~| 573 in June 2016 to ~| 984 levels in June 2021)....

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

26 Jul 2021

946.50

-1.42%

Revival in DF counterweighted by weak US performance

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Gross margin contracted by 390bp YoY to 71% in 1QFY22 due to increased competition in certain products. EBITDA margin contracted at a higher rate of 1,260bp YoY to 17.8% (est. 25.4%) due to higher operational cost (other...

Alembic Pharmaceuticals Ltd.'s price crossed below 100Day SMA today

Alembic Pharmaceuticals Ltd.

05 May 2021, 12:00AM

946.50

-1.42%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

ICICI Securities Limited

Q4 revenues grew 6.1% YoY to | 1280 crore with strong growth in RoW formulations and API segment being partly offset by 17.7% YoY decline in US sales to | 475 crore. Domestic formulations grew 4.7% YoY to | 358 crore. RoW sales grew a robust 76.5% YoY to | 233 crore whereas API segment grew 38.1% YoY to | 214 crore. EBITDA margins declined 45 bps YoY to 26.7% with lower gross margins being mostly offset by lower...

Alembic Pharmaceuticals Ltd.'s price crossed below 100Day SMA today

Alembic Pharmaceuticals Ltd.

05 May 2021, 12:00AM

946.50

-1.42%

COVID-led compliance delay at new sites moderates US outlook

Neutral: Alembic Pharmaceuticals Ltd.

Motilal Oswal

Alembic Pharma (ALPM)'s 4QFY21 operational performance was marginally below estimates, largely due to lower traction in US / Domestic Formulation (DF) sales. ALPM awaits feedback from the USFDA on the resolution of observations at the recently inspected injectables Unit (F3). We tweak our estimates for FY22/FY23, factoring in a) a slowdown in US sales and b) lower expensing of operational cost related to newer facilities. We continue to value ALPM at 19x 12M forward earnings to arrive at TP of INR1,070. We maintain Neutral on a limited upside from current levels....

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

05 May 2021, 12:00AM

946.50

-1.42%

Alembic Pharmaceutical - Company Update - US subdued, ROW surprises

Buy: Alembic Pharmaceuticals Ltd.

Target

Monarch Networth Capital Limited

We maintain BUY on Alembic Pharmaceuticals Ltd (ALPM') and increase our March FY22 TP to INR 1,480 (from INR 1,475 on modeling changes) thus an upside of 47% over the CMP. Q4FY21 results were on expected lines. Subdued US performance was on the back of headwinds coming from Sartans pricing erosion, which is likely to continue in the medium term. RoW business was a pleasant surprise on the back of low base post serialisation. Domestic continues to underperform due to Covid related headwinds; Specialty to lead the FY22 growth. Key medium term trigger would be USFDA's EIR for the general injectable plant which has already been audited by the USFDA on Feb-2021, deemed mission critical. Using DCF, we value Umbralisib at INR 160 per share discounting these sources of revenues including milestone based payments and CMP revenues over Umbralisibs commercial life. ALPM is currently trading at ~12x / ~9.6x EV / EBITDAx for FY22E / FY23E....

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

20 Jan 2021

946.50

-1.42%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Q3 results were a mixed bag. While operational performance was below Idirect estimates amid lower than expected International (mainly US) and API sales, net profit was higher due to higher-than-expected profit contribution from Rhizen Phama (one-off). Revenues grew 8.7% YoY to | 1314 crore led by strong growth in domestic, ROW formulations and API segment. US sales growth remained muted (down 0.6% YoY) at | 512 crore due to competition in Sartans. Domestic formulations grew 13.6% YoY to | 418 crore. EBITDA margins expanded 89 bps YoY to 27.8% due to better gross margins and lower R&D; cost. Subsequently, EBITDA grew 12.3% YoY to |...

Alembic Pharmaceuticals Ltd.'s price crossed below 100Day SMA today

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf